NervGen Pharma Corp. NGEN
- Market cap
- $217.2M
- P/E
- 0.0×
Follow NGEN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 0.65 | 0.55 | 1.05 | 1.10 | 1.10 | 1.20 | 1.50 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 1.76 | 2.49 | 2.67 | 2.54 | 2.52 | 2.99 | 5.60 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | 9 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (18) | (32) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (18) | (32) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.26) | (0.40) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.18) | (0.19) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.18) | (0.19) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.03 | 0.03 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 67 | 72 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (12) | (14) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | (12) | (14) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 2 | 2 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 0 | — |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | (13) | (16) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 2 | 2 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (204.82%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (1,445.47%) |
ROE
|
|||
NervGen Pharma Corp. (NGEN) key facts
- NervGen Pharma Corp. reported a net loss of $31.6 million, or a loss of $0.40 per share, for fiscal 2025.
- As of September 25, 2026, NGEN traded at $1.94, a market capitalization of $217.2 million.
- Return on equity was −1,445.5% and debt-to-equity 0.00.
NervGen Pharma Corp. (NGEN) Latest News
25 Sep
NervGen Pharma Corp. will restate its 2025 audited annual financials and its Q2 2026 interim statements to revalue warrants and options. The restatement reduces stock-based compensation expense, warrant liabilities, and accumulated deficit, and adjusts unrealized gains/losses on warrant derivatives. All changes are non-cash and do not affect cash, cash runway, or day-to-day operations. NervGen expects to file the restated 2025 statements (including 2024 comparatives and January 1, 2024 opening balances) and the restated Q2 2026 statements, and remains on track to report Q3 2026 results. The company’s focus on NVG-291 and other programs remains unchanged. Non-cash restatement alters reported costs and deficits without affecting cash or operations, likely yielding a moderate effect on investor sentiment and metrics.
26 May
NervGen Pharma Corp. (NGEN) announced positive independent blinded biomechanical gait analyses confirming genuine neural recovery with NVG-291 in the Phase 1b/2a CONNECT SCI study. Positive phase 2 data for lead drug NVG-291 can drive major gains in valuation and development momentum for spinal cord injury treatment.
21 May
NervGen Pharma Corp. prices a US$60.0 million public offering of securities. US$60 million capital raise supplies major funding to advance NervGen's drug development pipeline and operations.
NervGen Pharma Corp. (NGEN) announces a proposed public offering of securities. Proposed public offering supplies capital for operations while risking share dilution and short-term stock pressure.
7 Apr
NervGen Pharma secured FDA alignment after a successful End-of-Phase 2 meeting for the RESTORE Phase 3 registrational study of NVG-291 in chronic tetraplegia. FDA alignment on Phase 3 study advances NVG-291 toward potential approval and major revenue opportunity.
31 Mar
NervGen Pharma Corp. reported full year 2025 financial results and provided business updates. Standard financial results release can moderately sway short-term stock sentiment and outlook.
12 Mar
NervGen Pharma Corp. announces voluntary delisting from the TSX Venture Exchange. Voluntary delisting from TSX Venture Exchange represents a major strategic decision likely to impact stock liquidity and investor access.
4 Mar
NervGen Pharma appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs. Executive hires in regulatory and clinical roles strengthen operational capabilities for drug development and approvals.
9 Feb
NervGen Pharma appoints Adam Rogers as Chief Executive Officer to lead the company's growth and execution of its spinal cord injury mission. CEO appointment at NervGen Pharma may moderately affect operational execution and strategy in spinal cord injury programs.